FDA Flags High-Risk Issue with Erbe Flexible Cryoprobes
The FDA’s Center for Devices and Radiological Health (CDRH) has issued an Early Alert regarding a potentially high-risk issue involving certain flexible cryoprobes manufactured by Erbe USA.
Issue Overview
Erbe USA has identified a defect in specific cryoprobe models that may cause the device to rupture or burst during activation. The root cause of the issue is insufficient adhesive applied during manufacturing, resulting in excessive internal pressure leading to device failure
Risk to Patients and Users
A device rupture may result in a loud explosive sound, tinnitus or hearing loss (temporary or permanent) and burns or physical injury to patients or healthcare personnel.
As of February 24, five serious injuries were reported and no deaths were reported.
Required Actions (Immediate)
The FDA and manufacturer are advising all users to immediately discontinue use of affected devices, identify and quarantine impacted lot numbers, notify all relevant personnel and downstream users, and ensure redistributed products are tracked and recalled
Device Context
Flexible cryoprobes are used in interventional procedures for tissue destruction (cryotherapy), removal of foreign bodies, clots, and mucus plugs, tumor debulking, and biopsy support.
Given their use in critical airway and tissue procedures, device integrity is essential.
Regulatory Status
This is an FDA Early Alert, indicating a potentially high-risk issue under active review. Additional updates may follow as more data becomes available.
MDP Insight: What This Means for Manufacturers and Providers
This alert highlights several important regulatory and quality considerations.
Manufacturing Controls Matter
A seemingly minor issue, adhesive application, resulted in a high-risk device failure mode. This reinforces the importance of process validation, supplier/material controls, and production consistency.
Risk Management Must Address Use Conditions
Devices used under pressure or extreme conditions require robust design controls that include a failure mode analysis.
Field Action Execution Is Critical
Effective recall/notification processes must ensure rapid identification of affected lots, clear communication across distribution chains, and user awareness at the point of care.
Bottom Line
This event underscores how manufacturing variability can translate directly into patient risk, particularly in interventional devices. For manufacturers, it is a reminder that small process deviations can have large clinical consequences, and postmarket surveillance and rapid response systems are essential.
Download a list of recalled product lot numbers
FDA Warns Wild Arabic Herbs Over Product Cancer Claims
FDA Warns Wild Arabic Herbs Over Cancer Claims for Herbal Product FDA issued a warning letter to Wild Arabic Herbs after reviewing the company’s website and determining that its “Edral-17t” product was marketed as an unapproved new drug. FDA cited claims that the...
FDA Warns Amazon for Unapproved Drugs Sold On Its Website
FDA Issues Warning Letter to Amazon for Unapproved Drug Products FDA issued a warning letter to Amazon.com, Inc. after purchasing and reviewing products sold through Amazon’s website and fulfilled through Amazon’s logistics network. The products identified were...
FDA Warns Leading Edge Health Over Unapproved New Drugs
FDA Warning Letter Targets Erectin Stimulating Gel and VigRX Delay Wipes FDA issued a warning letter to Leading Edge Health Inc. after reviewing the company’s website and determining that two sexual health products were being marketed as unapproved new drugs. The...
FDA Targets Online Marketing of Unapproved Drugs
FDA Issues 14 Warning Letters Targeting Online Unapproved Drug Sales The U.S. Food and Drug Administration (FDA) has issued a coordinated series of warning letters targeting companies marketing unapproved drug products online, signaling an intensified enforcement...
FDA Approves First Treatment to Reduce Risk of Acute Pancreatitis
FDA Approves First Treatment Proven to Reduce Acute Pancreatitis Risk in Severe HypertriglyceridemiaAn important example of the distinction between surrogate endpoints and clinical outcomes in drug development The U.S. Food and Drug Administration (FDA) has approved...
Gas Station Drugs: The Regulatory Wild West
Walk into enough gas stations, smoke shops or convenience stores in America and eventually you will encounter a strange modern pharmacy hiding in plain sight. Brightly colored “energy shots.” “Herbal” sexual enhancement pills. Kratom capsules and concentrated...